Acta Med. 2014, 57: 30-33
https://doi.org/10.14712/18059694.2014.6
DENOSUMAB ASSOCIATED WITH BONE DENSITY INCREASE AND CLINICAL IMPROVEMENT IN A LONG-TERM HEMODIALYSIS PATIENT. CASE REPORT AND REVIEW OF THE LITERATURE
References
1. SR, San Martin J, McClung MR, et al: Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 33–41.
<https://doi.org/10.1056/NEJMoa0809493>
2. GA, Bone HG, Fang L et al: A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 2012; 27: 1471–1479.
<https://doi.org/10.1002/jbmr.1613>
<PubMed>
3. BB, Davis J, Burns KD: Severe hypocalcemia following denosumab injection in a hemodialysis patient. Am J Kidney Dis 2012; 60: 626–628.
<https://doi.org/10.1053/j.ajkd.2012.06.019>
4. JV: Dramatic increase in parathyroid hormone and hypocalcemia after denosumab in a kidney transplanted patient. Clin Kidney J 2013; 6: 122; doi 10:1093/ckj/sfs158
<https://doi.org/10.1093/ckj/sfs158>
<PubMed>
5. Ivanov P, Khedr M: Prolonged hypocalcemia following a single dose of 60 ug denosumab in two patients with CKD4/5 on cinacalcet treatment for tertiary hyperparathyroidism. Clin Kidney J 2013; doi:10.1093/ckj/sft014
<https://doi.org/10.1093/ckj/sft014>
<PubMed>
6. O, Cheungpasitporn W, Srivali N, et al: Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency. Am J Emergency Med 2013; 31: 756e1–756e2.
7. DB: Severe hypocalcemia following a single injection of denosumab in a patient with renal impairment. J Drug Assessment 2012; 1: 33–36.
<https://doi.org/10.3109/21556660.2012.668504>
<PubMed>
8. M, Csongradi E, Koch AC: Severe symptomatic hypocalcemia after denosumab administration in an end-stage renal disease patient on peritoneal dialysis with controlled secondary hyperparathyroidism. British J Med Medical Research 2013; 3: 1398–1406.
<https://doi.org/10.9734/BJMMR/2013/2989>
9. R, Ketteler M, Brandenburg VM: Anti-RANKL therapy – implications for the bone-vascular-axis in CKD? Denosumab in post-menopausal women with low bone mineral density Nephrol Dial Transplant 2006: 21: 2075–2077.
10. M, Kazama JJ, Shigematsu T et al: Skeletal resistance to PTH as a basic abnormality underlying uremic bone disease. Am J Kidney Dis 2001; 38: 152–155.
<https://doi.org/10.1053/ajkd.2001.27426>
11. M, la Piedra C, Fernandez C et al: Association between phosphate removal and markers of bone turnover in haemodialysis patients. Nephrol Dial Transplant 2006; 21: 1626–1632.
<https://doi.org/10.1093/ndt/gfl034>
12. S, Montagnani A, Caffarelli C, et al. Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis. J Endocrinol Invest 2005; 28: 534–539.
<https://doi.org/10.1007/BF03347242>
13. JJ, Kato H, Sato T, et al: Circulating osteoprotegerin is not removed through haemodialysis membrane. Nephrol Dial Transplant 2002; 17: 1860–1861.
<https://doi.org/10.1093/ndt/17.10.1860>
